Skip to main content

Advertisement

SpringerLink
Log in

Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

Describe the consequences of dextropropoxyphene (DXP) market withdrawal on analgesic prescriptions and on the quality of therapeutic management of chronic pain.

Patients and methods

From a cohort of non-institutionalised elderly patients with chronic pain recruited by general practitioners, we selected patients who were treated with DXP daily for at least 6 months just prior to DXP market withdrawal and who had an evaluation of pain and its impact on daily activities before and after DXP withdrawal.

Results

One hundred three patients took DXP daily for chronic pain. Immediately after DXP market withdrawal, 42 (40.8 %), 55 (53.4 %) and 3 (2.9 %) patients were treated with step 1, 2 and 3 analgesics, respectively, and 3 patients (2.9 %) were no longer receiving any analgesic medication. Among the 55 patients who continued on step 2 analgesics, 37 were treated with tramadol, 14 with codeine and 9 with opium. Pain intensity and the impact of pain on daily activities remained stable.

Conclusion

DXP market withdrawal had no consequences on the intensity or impact of chronic pain in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gaubert S, Vie M, Damase-Michel C, Pathak A, Montastruc JL (2009) Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption. Fundam Clin Pharmacol 23:247–252

    Article  CAS  PubMed  Google Scholar 

  2. Tavassoli N, Lapeyre-Mestre M, Sommet A, Montastruc JL (2009) Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol). Br J Clin Pharmacol 68:422–426

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Li Wan Po A, Zhang WY (1997) Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. Bmj 315:1565–1571

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Hawton K, Bergen H, Simkin S, Wells C, Kapur N, Gunnell D (2012) Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study. PLoS Med 9:e1001213

    Article  PubMed Central  PubMed  Google Scholar 

  5. Corcoran P, Reulbach U, Keeley H, Perry I, Hawton K, Arensman E (2010) Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market. BMC Clin Pharmacol 10:6–10

    Article  PubMed Central  PubMed  Google Scholar 

  6. Handley SA, Flanagan RJ (2014) Drugs and other chemicals involved in fatal poisoning in England and Wales during 2000-2011. Clin Toxicol (Phila)

  7. Bismuth S, Leng EL, Oustric S, Montastruc JL, Lapeyre-Mestre M (2011) Which analgesic after dextropropoxyphene withdrawal? A survey in a sample of general practitioners in southwest of France. Therapie 66:25–28

    Article  PubMed  Google Scholar 

  8. Becquemont L, Benattar-Zibi L, Bertin P, Berrut G, Corruble E, Danchin N, Delespierre T, Derumeaux G, Falissard B, Forette F, Hanon O, Pasquier F, Pinget M, Ourabah R, Piedvache C (2013) National observatory on the therapeutic management in ambulatory care patients aged 65 and over, with type 2 diabetes, chronic pain or atrial fibrillation. Therapie 68:265–283

    Article  PubMed  Google Scholar 

  9. Bertin P, Becquemont L, Corruble E, Derumeaux G, Falissard B, Hanon O, Pinget M, Forette F (2013) The therapeutic management of chronic pain in ambulatory care patients aged 65 and over in France: the S.AGES Cohort. Baseline data. J Nutr Health Aging 17:681–686

    Article  CAS  PubMed  Google Scholar 

  10. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. Jama 185:914–919

    Article  CAS  PubMed  Google Scholar 

  11. Alby M-A, Bardin T, Bensoussan J-L, Biour M, Bruxelle J, Cunin G, Deveaux M, Diquet B, Doucet J, Eschalier A, Jacquot F, Lepine J-P, Levy P, Liard L, Mallaret M, Morel G, Moutarde A, Orcel P, Perrot S, Sautet A, Saviuc P, Sichere P, Vergne-Salle P, Volckmann P, Castot A, Veyries M-L, Deguines C, Lavergne V, Deleau N, Dubosq A, Courne M-A (2011) Prise en charge des douleurs de l’adulte modérées à intenses: Recommandations après le retrait des associations dextropropoxyphène/paracétamol et dextropropoxyphène/paracétamol/caféine

Download references

Conflict of interest

Lazkani A, Delespierre T, Benattar-Zibi L, Sophie Bucher, Ourabah R and Piedvache C have no conflict of interest. Becquemont L received consulting fees from Sanofi-Aventis, Pfizer, Servier and lecture fees from Genzyme, GlaxoSmithKline, Bristol-Myers Squibb, Merck Sharp and Dohme. Close family member working at Sanofi France. Bauduceau B received consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, Merck Sharp and Dohme, Roche, Novo Nordisk. Bertin P received consulting fees from Sanofi-Aventis, Pfizer, Ethypharm, Reckitt-Benkiser and speaking fees from Genevrier, Roche, Bristol-Myers Squibb, Merck Sharp and Dohme. Berrut G received fees from Sanofi, Lundbeck, Eisai, Novartis, Merck Sharp and Dohme, Amgen, Boehringer-Ingelheim, Bayer. Corruble E received consulting fees from Servier, Lundbeck, Sanofi-Aventis, Bristol Myers Squibb, Eisai. Danchin N received consulting or speaking fees from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, MSD-Schering Plough, Novartis, Novo Nordisk, Pierre Fabre, Pfizer, Roche, Sanofi-Aventis, Servier, Takeda, and The Medicines Company. Derumeaux G received consulting or speaking fees from Actelion, Boehringer-Ingelheim, Pfizer, Sanofi-Aventis, and Servier, Research grant from Actelion and Astra Zeneca. Doucet J received speaking fees from Novo Nordisk, consulting fees from Sanofi-Aventis, Novo Nordisk, Merck-Serono and research partnership with Lilly. Falissard B received consulting fees from Sanofi-Aventis, Servier, Roche, AstraZeneca, Grünenthal, Lilly, HRA, Boeringher-Ingelheim, Bayer, Novartis, Genzyme, Stallergenes, Daiichi, Otsuka, Bristol-Myers Squibb. Forette F received speaking and consulting fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Eisai, Exonit Fabre, Ipsen, Janssen-Cilag, Lilly, Lundbeck, Novartis, Merck Sharp and Dohme, Merz, Pfizer, Roche, Sanofi-Aventis, Servier, Schwarz Pharma, Specia, Warner-Lambert, Wyeth. Hanon O received speaking and consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer, Eisai, Exonit, Janssen-Cilag, Lundbeck, Novartis, Pfizer, Sanofi-Aventis, Servier. Pasquier F: investigator for Eisai, ExonHit, Novartis, Ipsen, Medivation, Pfizer, Bayer, Noscira, Sanofi, Roche, GE Healthcare. Consulting fees from Lilly, Bayer, Janssen, Sanofi. Pinget M received speaking and consulting fees from Asdia, AstraZeneca, Bristol-Myers Squibb, Medtronic, Merck Sharp and Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Ypsomed.

Author information

Authors and Affiliations

  1. Pharmacology Department, Faculty of Medicine Paris-Sud, Assistance Publique-Hôpitaux de Paris, Hopital Bicêtre, University Paris-Sud,, Le Kremlin-Bicêtre, France

    Laurent Becquemont, Tiba Delespierre, Aida Lazkani & Celine Piedvache

  2. Endocrinology Department, Hôpital Bégin, Saint-Mandé, France

    Bernard Bauduceau

  3. ORPEA/CLINEA, Puteaux, France

    Linda Benattar-Zibi

  4. Clinical Gerontology, University Hospital Center, Nantes, France

    Gilles Berrut

  5. INSERM U 669, Faculty of Medicine Paris-Sud, Department of Psychiatry, Bicêtre University Hospital, Assistance Publique–Hôpitaux de Paris, University Paris-Sud, Le Kremlin Bicêtre, France

    Emmanuelle Corruble

  6. HEGP, Coronary Diseases, Paris, France

    Nicolas Danchin

  7. Cardiovascular Functional Exploration, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France

    Geneviève Derumeaux

  8. Internal Medicine, Geriatry and Therapeutic, Saint Julien University Hospital, Rouen University, Rouen, France

    Jean Doucet

  9. INSERM U 669, Faculty of Medicine Paris-Sud, Biostatistics Department, Assistance Publique-Hôpitaux de Paris, Hopital Paul Brousse, University Paris-Sud, Le Kremlin-Bicêtre, France

    Bruno Falissard

  10. National Foundation of Gerontology, University Paris Descartes, Paris, France

    Francoise Forette

  11. EA 4468, AP-HP, Hôpital Broca, Geriatrics Department, University Paris Descartes, Paris, France

    Olivier Hanon

  12. UDSL, EA 1046, University Hospital Center, University of Lille Nord de France, Lille, France

    Florence Pasquier

  13. Endocrinology, Diabetes and Diseases of Nutrition (Pôle NUDE), University Hospital of Strasbourg and the European Centre for the Study of Diabetes (CeeD), University of Strasbourg, Strasbourg, France

    Michel Pinget

  14. General Practice Department, Faculty of Medicine Paris-Sud, University Paris-Sud, Le Kremlin-Bicêtre, France

    Rissane Ourabah & Sophie Bucher

  15. Centre de Recherche Clinique, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275, Le Kremlin Bicetre Cedex, France

    Laurent Becquemont & Philippe Bertin

Authors
  1. Laurent Becquemont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiba Delespierre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard Bauduceau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linda Benattar-Zibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gilles Berrut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emmanuelle Corruble
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicolas Danchin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Geneviève Derumeaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean Doucet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bruno Falissard
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Francoise Forette
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Olivier Hanon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Florence Pasquier
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Michel Pinget
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Rissane Ourabah
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Sophie Bucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Aida Lazkani
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Celine Piedvache
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Philippe Bertin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Becquemont.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Fig. 1

(JPEG 111 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Becquemont, L., Delespierre, T., Bauduceau, B. et al. Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain. Eur J Clin Pharmacol 70, 1237–1242 (2014). https://doi.org/10.1007/s00228-014-1722-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-014-1722-x

Keywords

Search

Navigation